---
title: "Shanghai Junshi Biosciences Co., Ltd. (688180.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688180.SH.md"
symbol: "688180.SH"
name: "Shanghai Junshi Biosciences Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T08:58:33.815Z"
locales:
  - [en](https://longbridge.com/en/quote/688180.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688180.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688180.SH.md)
---

# Shanghai Junshi Biosciences Co., Ltd. (688180.SH)

## Company Overview

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company’s product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of tumors; JS105, an oral small molecule inhibitor targeting PI3K-a which is in phase III clinical trial to treat gynecological tumors; and JS107, an antibody-drug conjugate which is in phase III clinical trial for the treatment of gastrointestinal cancer. It also develops JS212, JS213, JS207, JS203, JS125, JS214, and JS214 which is in phase I/II clinical trial for the treatment of tumors; JS111, a small molecule inhibitor targeting which is in phase I/II clinical trial to treat NSCLC; JS110, a small molecule inhibitor of the nuclear export protein XPO1 which is in phase I/II clinical trial to treat endometrial cancer; JS007, a recombinant humanized anti-Cytotoxic T lymphocyte associated antigen-4 monoclonal antibody which is in phase I/II clinical trial to treat lung cancer and melanoma; and JT002, A small nucleic acid immunomodulator which is in phase I/II clinical trial for the treatment of seasonal allergic rhinitis. In addition, the company offers TUOYI/LOQTORZI/ZYTORVI for tumors; JUNMAIKANG for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn’s disease; VV116/JT001, an oral nucleoside analog drug; and JUNSHIDA to treat hyperlipidemia.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.junshipharma.com](https://www.junshipharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.50)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 20 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 31.72% |  |
| Net Profit YoY | 46.39% |  |
| P/B Ratio | 6.56 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 38723629280.04 |  |
| Revenue | 2728962114.42 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -11.48% | D |
| Profit Margin | -24.26% | E |
| Gross Margin | 79.76% | A |
| Revenue YoY | 31.72% | A |
| Net Profit YoY | 46.39% | B |
| Total Assets YoY | 29.87% | A |
| Net Assets YoY | 7.43% | B |
| Cash Flow Margin | 66.18% | C |
| OCF YoY | 31.72% | A |
| Turnover | 0.22 | D |
| Gearing Ratio | 56.97% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Junshi Biosciences Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "31.72%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "46.39%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.56",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "38723629280.04",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2728962114.42",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-11.48%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-24.26%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "79.76%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "31.72%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "46.39%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "29.87%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "7.43%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "66.18%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "31.72%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.22",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "56.97%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -58.49 | 70/81 | - | - | - |
| PB | 6.56 | 60/81 | 7.05 | 6.34 | 5.78 |
| PS (TTM) | 14.19 | 61/81 | 18.83 | 15.94 | 14.51 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-12T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Underweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 38.50 |
| Highest Target | 26.00 |
| Lowest Target | 26.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688180.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688180.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688180.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/688180.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**